Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Blood (2022) 140 (Supplement 1): 246–248.

https://doi.org/10.1182/blood-2022-165402

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Blood (2021) 138 (Supplement 1): 466.

https://doi.org/10.1182/blood-2021-146798

Published: 2021

Journal Articles

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Blood (2019) 134 (16): 1337–1345.

https://doi.org/10.1182/blood.2019000241

Published: 2019

Includes: Supplemental data

Journal Articles

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Blood (2017) 130 (Supplement 1): 567.

https://doi.org/10.1182/blood.V130.Suppl_1.567.567

Published: 2017

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Blood (2017) 130 (Supplement 1): 2017.

https://doi.org/10.1182/blood.V130.Suppl_1.2017.2017

Published: 2017

Journal Articles

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Marina Díaz-Beyá, MD PhD, Alfons Navarro, PhD, Salut Brunet, MD PhD, Josep F Nomdedeu, MD, Anna Cordeiro, Msc, Marta Pratcorona, MD PhD, Meritxell Nomdedeu, MD PhD, Ruth M Risueño, PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MDPhD, Rafael F. Duarte, MD PhD, Olga Salamero, MD, Lourdes Escoda, MD, David Gallardo, MD PhD, Carmen Pedro, MD, Josep M Marti-Tutusaus, Jorge Sierra, MD, Mariano Monzó, MD PhD, Jordi Esteve, MD PhD

Blood (2014) 124 (21): 1003.

https://doi.org/10.1182/blood.V124.21.1003.1003

Published: 2014

Journal Articles

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Josep F Nomdedeu, MD, Eulalia Puigdecanet, Elena Bussaglia, PhD, Juan J Hernandez, Maite Carricondo, Camino Estivill, Josep M Marti-Tutusaus, Mar Tormo, Lurdes Zamora, PhD, Josep-Maria Ribera, MD, PhD, Lara Nonell, Anna Aventin, MD, Francesc Sole, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 4813.

https://doi.org/10.1182/blood.V120.21.4813.4813

Published: 2012

Journal Articles

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Blood (2012) 120 (21): 1452.

https://doi.org/10.1182/blood.V120.21.1452.1452

Published: 2012

Journal Articles

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Josep F Nomdedeu, MD, Montserrat Hoyos, Maite Carricondo, Elena Bussaglia, PhD, Camino Estivill, Jordi Esteve, MD, PhD, Mar Tormo, Rafael F Duarte, MD, PhD, Olga Salamero, MD, PAZ Queipo De Llano, MD, Joan Bargay, Inmaculada Heras, Josep M Marti-Tutusaus, Andreu Llorente, Josep-Maria Ribera, MD, PhD, David Gallardo, MD, PhD, Anna Aventin, MD, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 2524.

https://doi.org/10.1182/blood.V120.21.2524.2524

Published: 2012

Journal Articles

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Blood (2010) 116 (21): 1066.

https://doi.org/10.1182/blood.V116.21.1066.1066

Published: 2010

Journal Articles

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Blood (2009) 114 (22): 4711.

https://doi.org/10.1182/blood.V114.22.4711.4711

Published: 2009

Journal Articles

Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML).

Blood (2005) 106 (11): 1855.

https://doi.org/10.1182/blood.V106.11.1855.1855

Published: 2005

Journal Articles

Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC).

Blood (2004) 104 (11): 2989.

https://doi.org/10.1182/blood.V104.11.2989.2989

Published: 2004

NARROW

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML).

Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only